About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Growth Hormone for the Treatment of Gastroparesis | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGEARLY Phase 1NCT06803589

Growth Hormone for the Treatment of Gastroparesis

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.

Lead sponsor: Mayo Clinic•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Guillermo GI Program Coordinator, Research

CONTACT

480-301-4679 barahona.guillermo@mayo.edu

Tisha Lunsford, MD

CONTACT

lunsford.tisha@mayo.edu

Sponsors

Lead Sponsor

Mayo Clinic

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Symptoms \> 6 months that have not responded satisfactorily to standard treatment.
•For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \>21

Exclusion Criteria

•Known history of GH deficiency, hypothalamic or pituitary disease
•Diabetes
•Prior use of GH therapy
•Age-adjusted low serum IGF1
•Women on oral estrogen therapy6
•Pregnancy or nursing
•History of malignant solid tumors
•Obesity (BMI \> 30)History of coronary and thromboembolic diseases.
•History of sarcoidosis
•History of pituitary surgery
•History of thyroid nodules.
•Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study.
•Failure to give informed consent.

Related studies

Study of Gastric Motility in Eosinophilic Gastritis

NCT05229432 · Eosinophilic Gastritis, Gastroparesis, and more

Gastroparesis Outcome Longitudinal Database Enrolled Numerically

NCT03876288 · Gastroparesis

To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.

NCT07287943 · Type 1 Diabetes, Gastroparesis Due to Diabetes Mellitus Type I

Correlation Between Advanced Glycation End Products and Gastric Motility Disorder in Diabetes Gastroparesis

NCT07324785 · Diabetic Gastroparesis

BSGM to Evaluate Patients With GI Symptoms

NCT05880199 · Gastrointestinal Motility Disorders in Children, Functional Gastrointestinal Disorders, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 16, 2026Terms

Trial snapshot

StatusRECRUITING

PhaseEARLY_PHASE1

Enrollment10

Start dateOct 2024

Last updatedApr 16, 2026

Condition

Locations shown

Mayo Clinic

Phoenix, Arizona

Mayo Clinic in Arizona

Scottsdale, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 16, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions